RU2003104522A - Применение штаммов parapoxvirus (парапокс-вируса) против органофиброзов - Google Patents
Применение штаммов parapoxvirus (парапокс-вируса) против органофиброзов Download PDFInfo
- Publication number
- RU2003104522A RU2003104522A RU2003104522/15A RU2003104522A RU2003104522A RU 2003104522 A RU2003104522 A RU 2003104522A RU 2003104522/15 A RU2003104522/15 A RU 2003104522/15A RU 2003104522 A RU2003104522 A RU 2003104522A RU 2003104522 A RU2003104522 A RU 2003104522A
- Authority
- RU
- Russia
- Prior art keywords
- organofibrosis
- human
- prophylactic
- parapox
- therapeutic effect
- Prior art date
Links
- 241000700639 Parapoxvirus Species 0.000 title claims 7
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 9
- 230000000069 prophylactic effect Effects 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 241000283898 Ovis Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000006978 adaptation Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000002161 passivation Methods 0.000 claims 3
- 230000003510 anti-fibrotic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Применение изолятов парапокс-вирусов для получения лекарственных средств с профилактическим или терапевтическим действием на органофиброзы человека.
2. Применение изолятов парапокс-вирусов, например, штаммов D1701, orf-11, Greek orf штамм176, Greek orf штамм 155, New Zeiand (NZ) штаммов для получения лекарственных средств с профилактическим или терапевтическим действием на органофиброзы человека.
3. Применение изолятов парапокс-вирусов по пп.1 и 2, где в качестве New Zeiand (NZ) штаммов используют штаммы NZ2, NZ7 и NZ10, для получения лекарственных средств с профилактическим или терапевтическим действием на органофиброзы человека.
4. Применение модифицированных путем пассирования или адаптации на соответствующих клетках парапокс вирусов по пп.1-3 для получения лекарственных средств с профилактическим или терапевтическим действием на органофиброзы человека.
5. Применение модифицированных путем пассирования или адаптации на соответствующих клетках парапокс-вирусов по пп.1-3 для получения лекарственных средств с профилактическим или терапевтическим действием на органофиброзы человека, причем для пассирования или адаптации используют клетки человека, такие как WI-38, MRC-5, бычьи клетки, такие как BK-K13A47/Reg или MDBK и овечьи клетки, такие как MDOK.
6. Применение частей или фрагментов вирусов по пп.1-5 для получения лекарственных средств с профилактическим или терапевтическим действием на органофиброзы человека, причем под частями понимаются экспримированные посредством соответствующих переносчиков, например вирусов вакцинии, в соответствующих системах, таких как фибробластклеточные культуры, геномные или субгеномные фрагменты, и под фрагментами понимаются полученные посредством биохимической очистки, такой как хроматография, фракции экспримированных или физически растворенных вирусных частичек.
7. Применение одного из изолятов по пп.1-6 в комбинации с другими средствами для получения лекарственных средств и фармацевтических препаратов с профилактическим или терапевтическим действием на органофиброзы человека.
8. Применение парапокс овис D 1701 самостоятельно или в комбинации с другими средствами для получения лекарственных средств и фармацевтических препаратов с профилактическим или терапевтическим действием на органофиброзы человека.
9. Применение парапокс овис D 1701 или препарата NZ2 в качестве стандарта для оценки антифиброзного действия в тестах на обнаружение антифиброзных субстанций.
10. Применение парапокс овис D 1701 по п.8, где фармацевтические препараты и лекарственные средства пригодны для орального введения.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10033581 | 2000-07-11 | ||
| DE10033581.0 | 2000-07-11 | ||
| DE10122233A DE10122233A1 (de) | 2000-07-11 | 2001-05-08 | Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen |
| DE10122233.5 | 2001-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003104522A true RU2003104522A (ru) | 2004-06-27 |
Family
ID=26006334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003104522/15A RU2003104522A (ru) | 2000-07-11 | 2001-07-11 | Применение штаммов parapoxvirus (парапокс-вируса) против органофиброзов |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6632647B2 (ru) |
| EP (1) | EP1303302B1 (ru) |
| JP (1) | JP5106736B2 (ru) |
| CN (1) | CN1452496B (ru) |
| AR (1) | AR028800A1 (ru) |
| AU (2) | AU8582701A (ru) |
| BG (1) | BG107447A (ru) |
| CA (1) | CA2415399C (ru) |
| CZ (1) | CZ200372A3 (ru) |
| DK (1) | DK200300014A (ru) |
| EE (1) | EE200300019A (ru) |
| FI (1) | FI20030038A (ru) |
| GB (1) | GB2383752B (ru) |
| HK (1) | HK1054330B (ru) |
| HR (1) | HRP20030097A2 (ru) |
| HU (1) | HU227668B1 (ru) |
| IL (1) | IL153826A0 (ru) |
| LT (1) | LT5064B (ru) |
| LU (1) | LU90996B1 (ru) |
| LV (1) | LV12991B (ru) |
| MA (1) | MA25765A1 (ru) |
| MX (1) | MXPA03000278A (ru) |
| NO (1) | NO20030081D0 (ru) |
| NZ (1) | NZ523535A (ru) |
| PL (1) | PL360839A1 (ru) |
| RU (1) | RU2003104522A (ru) |
| SE (1) | SE0300033L (ru) |
| SI (1) | SI21171A (ru) |
| SK (1) | SK382003A3 (ru) |
| WO (1) | WO2002004019A2 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| AU2002353031A1 (en) | 2001-12-07 | 2003-06-23 | Bayer Corporation | Use of parapox b2l protein to treat cancer and modify immune responses |
| US6752995B2 (en) * | 2002-04-15 | 2004-06-22 | Board Of Regents, The University Of Texas System | Nucleic acid and polypeptide sequences useful as adjuvants |
| EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2012045473A1 (en) * | 2010-10-07 | 2012-04-12 | Technische Universität München | Viruses for the treatment of fibrosis |
| EA201891848A1 (ru) * | 2016-02-16 | 2019-02-28 | Осака Юниверсити | Фармацевтическая композиция для применения в лечении фиброза |
| TW201919675A (zh) * | 2017-09-07 | 2019-06-01 | 德商艾庫瑞斯公司 | 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| US4360510A (en) * | 1979-11-30 | 1982-11-23 | Proctor Julian W | Method for screening anti-tumor agents of the reticulo-endothelial stimulant class |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| DE3504940C2 (de) | 1984-02-17 | 1997-11-06 | Bayer Ag | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel |
| DE3816139A1 (de) * | 1987-10-17 | 1989-04-27 | Bayer Ag | Verfahren zur herstellung von paramunitaetsinducern |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PT885013E (pt) * | 1996-04-15 | 2002-01-30 | Anton Mayr Prof Dr Med Vet Dr | Utilizacao de indutores de para-imunidade multipotentes baseados em poxvirus ou parapoxvirus atenuados e nao imunogenicos para a fabricacao de medicamentos |
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| IL139593A (en) * | 2000-11-09 | 2010-12-30 | Biogem Optical Ltd | Method for the detection of viable microorganisms |
-
2001
- 2001-07-11 SI SI200120047A patent/SI21171A/sl not_active IP Right Cessation
- 2001-07-11 EP EP01965110A patent/EP1303302B1/de not_active Expired - Lifetime
- 2001-07-11 US US09/903,005 patent/US6632647B2/en not_active Expired - Lifetime
- 2001-07-11 SK SK38-2003A patent/SK382003A3/sk not_active Application Discontinuation
- 2001-07-11 AU AU8582701A patent/AU8582701A/xx active Pending
- 2001-07-11 GB GB0302629A patent/GB2383752B/en not_active Expired - Lifetime
- 2001-07-11 EE EEP200300019A patent/EE200300019A/xx unknown
- 2001-07-11 NZ NZ52353501A patent/NZ523535A/xx unknown
- 2001-07-11 WO PCT/EP2001/007978 patent/WO2002004019A2/de active IP Right Grant
- 2001-07-11 AU AU2001285827A patent/AU2001285827B2/en not_active Expired
- 2001-07-11 MX MXPA03000278A patent/MXPA03000278A/es active IP Right Grant
- 2001-07-11 PL PL36083901A patent/PL360839A1/xx not_active Application Discontinuation
- 2001-07-11 AR ARP010103291A patent/AR028800A1/es not_active Application Discontinuation
- 2001-07-11 IL IL15382601A patent/IL153826A0/xx active IP Right Grant
- 2001-07-11 CN CN018151272A patent/CN1452496B/zh not_active Expired - Lifetime
- 2001-07-11 HU HU0303830A patent/HU227668B1/hu not_active IP Right Cessation
- 2001-07-11 CZ CZ200372A patent/CZ200372A3/cs unknown
- 2001-07-11 JP JP2002508473A patent/JP5106736B2/ja not_active Expired - Lifetime
- 2001-07-11 CA CA2415399A patent/CA2415399C/en not_active Expired - Lifetime
- 2001-07-11 LU LU90996A patent/LU90996B1/en active
- 2001-07-11 RU RU2003104522/15A patent/RU2003104522A/ru not_active Application Discontinuation
-
2003
- 2003-01-08 NO NO20030081A patent/NO20030081D0/no not_active Application Discontinuation
- 2003-01-08 BG BG107447A patent/BG107447A/bg unknown
- 2003-01-10 DK DK200300014A patent/DK200300014A/da not_active Application Discontinuation
- 2003-01-10 FI FI20030038A patent/FI20030038A/fi not_active IP Right Cessation
- 2003-01-10 MA MA26995A patent/MA25765A1/fr unknown
- 2003-01-10 SE SE0300033A patent/SE0300033L/xx not_active Application Discontinuation
- 2003-02-03 LT LT2003008A patent/LT5064B/lt not_active IP Right Cessation
- 2003-02-10 HR HR20030097A patent/HRP20030097A2/xx not_active Application Discontinuation
- 2003-02-11 LV LVP-03-13A patent/LV12991B/lv unknown
- 2003-09-15 HK HK03106614.0A patent/HK1054330B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mantlo et al. | Antiviral activities of type I interferons to SARS-CoV-2 infection | |
| Zhou et al. | Virus infection and death receptor-mediated apoptosis | |
| EP1453956B1 (en) | Method for large scale production of virus antigen | |
| Bera et al. | Zoonotic cases of camelpox infection in India | |
| Alexander et al. | The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577 | |
| Weltzin et al. | Clonal vaccinia virus grown in cell culture as a new smallpox vaccine | |
| US8445270B2 (en) | Immortalized avian cell lines and use thereof | |
| Saoo et al. | Antiviral activity of aloe extracts against cytomegalovirus | |
| EP1217891A4 (en) | THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE | |
| Janelle et al. | Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy | |
| Koyama et al. | Virus multiplication and induction of apoptosis by Sendai virus: role of the C proteins | |
| JP2004517807A5 (ru) | ||
| RU2003104522A (ru) | Применение штаммов parapoxvirus (парапокс-вируса) против органофиброзов | |
| RU2003104525A (ru) | Применение штаммов вируса parapox ovis для получения антивирусных и противораковых лекарственных средств | |
| DE69716741T2 (de) | Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten | |
| Chen et al. | Efficient reactivation of latent herpes simplex virus from mouse central nervous system tissues | |
| Hilliard et al. | Herpesvirus simiae (B virus): replication of the virus and identification of viral polypeptides in infected cells | |
| CN113398219A (zh) | 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途 | |
| DK0885013T3 (da) | Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler | |
| Manischewitz et al. | The effect of mycoplasmas on replication and plaquing ability of Herpes simplex virus | |
| Puthanakit et al. | Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy | |
| Wainwright et al. | Plaque assay for lymphocytic choriomeningitis virus based on hemadsorption interference | |
| CN105726525B (zh) | 含Merochlorin A结构的化合物在制备抗埃博拉病毒感染药物中的应用 | |
| Murayama et al. | In Vitro Anti‐Cytomegalovirus Activity of Kampo (Japanese Herbal) Medicine | |
| Conti et al. | Effect of concanavalin A on the early events of rabies virus infection of CER cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060110 |